Morpho has initiated the proposal vote for "Allocating 90,000 MORPHO to develop the ezETH/WETH market"

Orion Marine Group recently released its 2026 financial guidance, which fully demonstrates the strong appeal of its end markets and its solid strategic positioning.

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

Moderna, Inc. (MRNA) has recently updated its financial outlook, announcing an adjustment of its expected cash and cash equivalents at the end of 2026 to a range of $4.5 billion to $5.0 billion.

Industry Weekly Report: US API Crude Oil Inventories Increased by Over 5.6 Million Barrels Last Week